SLC5A2 and congestive heart failure: The notion of early initiation and sustained use of SGLT2 inhibitors (SGLT2i) in ACS is alluring, given the multiple suggested mechanistic effects that could potentially alter the disease's natural progression and mitigate the risk of progressing to end-stage heart disease and chronic heart failure [7].